Ads like these are all over social media. Too often, doctors warn, the companies behind the ads appear to prioritize business ...

The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

A nutrition scientist is calling out the growing wave of "nature's Ozempic" and other quick-weight loss products, calling out ...

Novo Nordisk launched "My Ozempic® Era" today, a national campaign which spotlights the longstanding Ozempic® patient ...

In her last week at AdExchanger, Senior Editor Alyssa Boyle reflects on three years of change, and stasis, in the CTV space.

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy, the diabetes and obesity treatments, revealed data showing that its new weight-loss drug candidate ...

A fast-growing body of research signals potential health benefits of GLP-1s, the class of diabetes and weight-loss drugs known by names like Ozempic, beyond what they were initially approved to treat.

Languages: English According to a public Con Edison docket on benefits, customers can expect a rate hike of up to 14 percent as employee welfare costs related to Ozempic and similar medications surge.

Some people have critiqued Ozempic (semaglutide)—a diabetes medication that can aid in weight loss—for the effects it has on the skin. Some people have reported "Ozempic face" and "Ozempic ...